key: cord-0039503-q8bkhhbl
authors: Munger, John S.; Rom, William N.
title: Fibrogenesis
date: 2010-05-21
journal: Molecular Pathology of Lung Diseases
DOI: 10.1007/978-0-387-72430-0_46
sha: 2cd3bc58106dafddfe933f2fa2c45c74b47e6e9c
doc_id: 39503
cord_uid: q8bkhhbl

Pulmonary fibrosis can be idiopathic or secondary to inflammatory states or injuries (Table 46.1). The tempo ranges from insidious to rapid, and the location of the fibrous tissue can be centered around or in the airways (bronchiolitis obliterans) or in the alveolar compartment (idiopathic pulmonary fibrosis [IPF]). In this chapter, we focus on IPF, the paradigmatic fibrosing lung disorder.

with oxygen and a transition metal to form an activated complex, which binds and cleaves DNA. Activated bleomycin can also damage proteins and lipids, in part by release of hydroxyl radicals. Bleomycin toxicity is most prominent in the lung; vascular injury, cell death, and infl ammation occur acutely, followed by collagen deposition. The pathology is more similar to the acute respiratory distress syndrome (ARDS) than it is to IPF. Other fi brosis models utilize radiation exposure; intratracheal silica, asbestos, or fl uorescein isothiocyanate; and adenoviral or transgenic expression of transforming growth factor (TGF)-β or interleukin (IL)-13.

Most experimental models consist of two components: an injury and a fi brotic response. In most models the injury is severe, associated with infl ammation, and produces fi brosis rapidly. Hence, these are poor models of the postulated initial injury in IPF, which is so subtle that it has not yet been identifi ed. Only one model has been reported that reproduces many of the histologic features of UIP/IPF: interferon-γ receptor knockout mice (which preferentially develop a Th2 cytokine response) chronically infected with murine γ-herpesvirus 68 (MHV68). 3 Using these models, in particular the murine bleomycin model, investigators have identifi ed many factors involved in fi brosis. For example, around 40 different knockout mice have an altered fi brotic response in the bleomycin model (Table 46. 2).

Introduction Pulmonary fi brosis can be idiopathic or secondary to infl ammatory states or injuries (Table 46 .1). The tempo ranges from insidious to rapid, and the location of the fi brous tissue can be centered around or in the airways (bronchiolitis obliterans) or in the alveolar compartment (idiopathic pulmonary fi brosis [IPF] ). In this chapter, we focus on IPF, the paradigmatic fi brosing lung disorder.

Early attempts to explain IPF emphasized infl ammation ("alveolitis") and the effects of infl ammatory and profi brotic cytokines. 1 The current consensus proposes instead that an initial epithelial injury provokes a wound repair response (Figure 46 .1). Instead of restoring normal tissue architecture, in some cases the repair process goes awry, and persistent matrix deposition ensues; in turn, these events may produce signals that further damage epithelium. 2 Experimental models have allowed us insight into many cellular processes and molecular mediators that are triggered by injury and lead to fi brosis in susceptible animals. What remains elusive is the nature of the inciting injury in IPF and the host and environmental factors that determine whether the response to injury is adaptive or maladaptive.

Animal models are valuable for testing the roles of specifi c molecules by using genetically altered mice or administering a specifi c factor or inhibitor; testing potential therapeutic compounds; distinguishing between the roles of resident lung cells and marrow-derived cells; and assessing the genetic factors through comparative genetics studies (e.g., linkage analysis using intercrosses of fi brosis-prone and fi brosis-resistant strains of mice).

Bleomycin, given either intratracheally or systemically, is the most commonly used model. Bleomycin interacts extent of fi broblastic foci in IPF lung biopsy material predicts mortality (the extent of fi brosis and infl ammation, in contrast, do not). 2 Fibroblastic foci are relatively small collections of fi broblasts (as few as 3, up to 30 or more) located just below the alveolar gas-tissue interface ( Figure 46 .2). Infl ammatory cells are rarely present. The fi broblasts are arranged parallel to the alveolar surface and are often hypertrophied. The fi broblasts stain for procollagen I and for cellular fi bronectin, indicative of active matrix protein synthesis. The fi broblasts also express α-smooth muscle actin, indicating that they are contractile myofi broblasts. The remnants of a basement membrane, identifi able by collagen IV staining, are typically present below the fi broblastic focus, indicating that the fi broblasts have migrated into the alveolar space. If basement membrane can be identifi ed at the epithelial layer rather than buried within the focus, it is frequently interrupted and distorted. Occasionally, two or three layers of basement membrane are detectable within a focus, suggesting repeated episodes of fi broblast invasion and epithelial repair. Fibrin is often present, indicating leakage of plasma.

The epithelium overlying fi broblastic foci is abnormal. The epithelial cells are cuboidal and hyperplastic. A basement membrane is often lacking, placing epithelial cells in direct contact with fi broblasts. Perhaps as a result, the epithelial cells are poorly adherent. In addition, by morphologic criteria and in situ end labeling, many epithelial cells are apoptotic or necrotic; dead or dying epithelial cells are preferentially located at fi broblastic foci. 5 Paradoxically, the underlying myofi broblasts are not apoptotic.

These observations suggest that an initial epithelial injury leads to a disruption of the normal barrier of the alveolus, with formation of a fi brin-rich exudate that is Figure 46 .1. The current conceptual model of fi brogenesis in idiopathic pulmonary fi brosis. An inciting factor causes epithelial injury. Depending on the nature and repetitiveness of the injury, as well as genetic and environmental factors, the injury undergoes either normal repair or an abnormal repair process with associated fi brosis. Signals related to the abnormal repair process (e.g., oxidative stress or angiotensin II) may cause further epithelial injury. Note: C5, complement factor 5; CysLT2, cysteinyl leukotriene 2; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; Nrf2, nuclear factor E2 p45-related factor 2; PAI-1, plasminogen activator inhibitor-1; PAR-1, proteaseactivated receptor-1; SPARC, secreted protein, acidic and rich in cysteine; SP-C, surfactant protein C; TAFI, thrombin-activatable fi brinolysis inhibitor; TGF, transforming growth factor; TNF, tumor necrosis factor. then invaded by activated, contractile fi broblasts (see Figure 46 .2). The perpetuation of fi broblast activation, matrix synthesis and contraction, accompanied by epithelial cell death, defi nes the pathobiology of IPF. Many laboratory investigators have compared IPF and normal lung fi broblasts. These studies consistently fi nd that IPF fi broblasts behave differently in culture-but not always in the same way. For example, IPF fi broblast growth rates have been reported as increased and decreased compared with normal fi broblasts. 2 Several proteins are selectively expressed by IPF fi broblasts, including discoidin domain receptor 1 (a receptor tyrosine kinase that binds collagen), 6 fi broblast activation protein α (a membrane protease). 7 and Thy-1.

Thy-1 is a glycosylphosphatidylinositol-anchored cell surface protein expressed on many cells, including some fi broblasts. 8 It is a ligand for several integrins, interacts with signaling molecules such as the Src family kinase cfyn, and localizes to lipid rafts. Cross-linking Thy-1 with antibodies triggers apoptosis. The activated fi broblasts in fi broblastic foci are Thy-1 negative, whereas most fi bro-blasts in normal human lung are Thy-1 positive. Thy-1 knockout mice are generally healthy; however, upon challenge with bleomycin, Thy-1 knockout mice develop increased fi brosis. In addition, absence of Thy-1 expression in lung fi broblasts correlates with higher TGF-β expression, the ability to activate latent TGF-β in response to fi brogenic stimuli, increased expression of the plateletderived growth factor-α receptor, enhanced migration, and increased α-smooth muscle actin expression. 8 

Three sources of the increased number of fi broblasts in interstitial lung disease have been proposed: proliferation of existing interstitial fi broblasts, transdifferentiation of epithelial cells into fi broblasts (epithelial-mesenchymal transition), and bone marrow-derived precursor cells referred to as circulating fi brocytes. The relative contribution of each source is not known for lung fi brosis models, but in a model of kidney fi brosis (unilateral ureteral obstruction) it was estimated that approximately one third of interstitial fi broblasts derived from epithelialmesenchymal transition and one sixth originated from bone marrow. 9 Circulating fi brocytes constitute <1% of circulating leukocytes and express a distinctive set of proteins, including collagens I and III, vimentin, CD34, CD45, CXCR4, CXCR7, major histocompatibility complex class II, and CD86. 10, 11 When cultured, fi brocytes adopt a spindle shape, continue to express extracellular matrix proteins, and become α-smooth muscle actin positive; TGF-β enhances these changes. The fi brocytes undergo chemotaxis in response to the chemokines CCL21 and CXCL12 and are recruited from the circulation to sites of tissue injury, including the lung.

In two models, the degree of lung fi brosis correlated with the extent of fi brocyte recruitment. Phillips et al. showed that fi brocytes are recruited to lung in the bleomycin model, that the kinetics of recruitment parallel collagen deposition, and that blocking recruitment of fi brocytes with anti-CXCL12 antibody reduces fi brosis. 12 Similarly, Moore and colleagues found, in the fl uorescein isothiocyanate-induced lung fi brosis model, that fi brocytes are recruited to the lung in a CCL12-and CCR2dependent manner and that CCR2 knockout mice have reduced lung fi brosis. 13 Epithelial-mesenchymal transition may also be a source of fi broblasts in lung fi brosis. The fact that TGF-β, a key mediator of fi brosis, induces epithelial-mesenchymal transition in a variety of epithelial cells in cell culture, including alveolar type 2 (AT2) cells, 14, 15 lends appeal to this idea. Willis and colleagues have presented evidence that epithelial-mesenchymal transition occurs in human IPF lung based on the identifi cation, by three-dimensional deconvolution microscopy, of cells that coexpress epithelial and mesenchymal markers. 14 

Oxidative Stress Lung cells must deal with a signifi cant oxidant load derived from high oxygen tension, inhaled substances (e.g., tobacco smoke, ozone, and particulates), and activated leukocytes. 16 Endogenously generated oxidants include superoxide (O 2 − ), hydrogen peroxide (H 2 O 2 ), hypochlorous acid (HOCl), and hydroxyl radical (OH . ). Oxidants modify biologic macromolecules, potentially leading to cellular dysfunction and death. In addition, the redox state can alter gene expression via effects on redoxsensitive transcription factors such as nuclear factor-κB and activator protein-1. Defenses against oxidants include superoxide dismutases, which convert O 2 − to H 2 O 2 ; catalase and other enzymes that decompose H 2 O 2 ; and antioxidants such as glutathione, a tripeptide derived from glutamate, cysteine, and glycine. Glutathione concentrations in epithelial lining fl uid (≈400 μM) are approximately two orders of magnitude higher than in nonlung extracellular fl uids and plasma, and within cells glutathione constitutes ≈90% of the nonprotein thiol groups. 16 Circumstantial evidence suggests that alterations in redox balance promote fi brosis. Many agents that induce fi brosis (e.g., asbestos, silica, bleomycin, ionizing radiation) produce reactive oxygen species (ROS) directly. Infl ammatory cells from IPF lungs produce higher concentrations of oxidants than normal cells, and lavage fl uid from IPF patients contains a high level of 8-isoprostane, a product of lipid peroxidation widely used as a marker of oxidative stress. Epithelial lining fl uid from IPF patients has a reduced glutathione concentration (≈25% of normal). 17 There are compelling links between redox biology and the fi brotic process. Transforming growth factor-β, a key profi brotic cytokine, causes reduced expression of γglutamyl cysteine synthetase, the rate-limiting enzyme for glutathione production, and induces the production of ROS by myofi broblasts isolated from IPF lung. 18 In addition, the latent form of TGF-β is activated by ROS. 19 Mice defi cient in the redox-regulated transcription factor Nrf2, which is involved in the expression of several antioxidant enzyme systems, have increased fi brosis after bleomycin injury. 20 Reactive oxygen species can increase proliferation of fi broblasts and cause epithelial cell death.

There is also evidence that enhancing lung antioxidant functions reduces fi brosis. Administration of superoxide dismutase, or small molecules with superoxide dismutase activity, reduces fi brosis in several models. Because the availability of cysteine is rate limiting for glutathione synthesis, N-acetyl cysteine, which is converted to cysteine, has been used to augment glutathione levels. N-acetyl cysteine attenuates bleomycin-induced lung infl ammation and subsequent fi brosis in mice and stabilizes lung function in IPF patients. 21 Apoptosis Apoptosis is a form of programmed cell death characterized by activation of a set of cysteine proteases (caspases), packaging of the cell remnants into membranebound vesicles that are taken up by surrounding cells, and lack of an infl ammatory response. 22 Apoptosis is conceptually distinct from another form of programmed cell death (autophagy) and from nonprogrammed cell death (necrosis), although in practice these forms of cell death are often not clearly distinguishable. Triggers of apoptosis involve extrinsic signals that trigger tumor necrosis factor receptor superfamily members with a death domain (e.g., the Fas receptor) and/or intrinsic signals such as DNA damage that cause release of mitochondrial cytochrome c and subsequent activation of a caspase cascade. Apoptosis can be induced by interruption of normal cell adhesion to the extracellular matrix, a process referred to as anoikis.

Increased numbers of apoptotic epithelial cells are present in IPF lungs, particularly adjacent to fi broblastic foci, but also in relatively normal areas of lung. 5, 22 In animal models, apoptosis is causally related to fi brosis. Inhibition of apoptosis with the broad-spectrum caspase inhibitor zVADfmk inhibits fi brosis in the bleomycin model. The role of apoptosis has also been studied in mice with an inducible TGF-β transgene expressed in lung epithelium; TGF-β expression in these mice causes a wave of apoptosis, followed by fi brosis, both of which are blocked by zVADfmk. 23, 24 Finally, intratracheal administration of an activating anti-Fas antibody, which binds to Fas expressed on epithelial cells, leads to lung epithelial cell apoptosis and fi brosis. 22 There are several possible causes for increased numbers of apoptotic epithelial cells in IPF. Epithelial cells overlying a fi broblastic focus may undergo anoikis. Li and colleagues showed that IPF myofi broblasts release angiotensin II, which triggers epithelial cell apoptosis, and captopril prevents fi brosis in several rodent models. 25 Oxidant stress and TGF-β signaling may also contribute to epithelial apoptosis. In patients with mutations in the gene encoding surfactant protein-C (SP-C), cellular dysfunction and the endoplasmic reticulum stress response may cause apoptosis of AT2 cells, and one can speculate that protein misfolding or traffi cking abnormalities in AT2 cells might occur in IPF due to environmental and/or genetic factor(s). Vandivier and colleagues suggest that impaired apoptotic cell removal may also be a factor. 26 How epithelial cell apoptosis leads to fi brosis is not known. A simple explanation is that loss of epithelial barrier function leads to formation of a fi brinous exudate followed by an abnormal fi broblast response. Also, apoptotic cells or the cells that engulf them can release the profi brotic cytokine TGF-β, 26 triggering other cellular and biochemical changes that promote development of fi brosis.

Transforming Growth Factor-β Transforming growth factor-β is a multifunctional cytokine involved in development, the immune system, matrix production, angiogenesis, and control of proliferation. Essentially all cells express TGF-β and have TGF-β receptors. Overwhelming evidence implicates TGF-β as a major factor in fi brosis. 27 Transforming growth factor-β levels are increased in IPF lung. In animal studies, overexpression of TGF-β in lung causes fi brosis, 24, 28 and interruption of TGF-β signaling prevents fi brosis in lung, 29, 30 kidney, skin, and liver models. There are three isoforms of TGF-β; TGF-β1 is the main isoform involved in the pathogenesis of fi brosis.

The activated TGF-β receptor complex has serine/ threonine kinase activity, and its major substrates are the receptor Smad (R-Smad) proteins Smad2 and Smad3. Phosphorylated R-Smads combine with a Co-Smad (Smad4), translocate to the nucleus, and, in conjunction with cell-and context-specifi c coactivators and corepressors, alter transcription of target genes. 31 Smad3 knockout mice have impaired fi brosis and wound healing responses.

Transforming growth factor-β is secreted in a latent form that results from noncovalent interaction between TGF-β and its propeptide (latency-associated peptide [LAP]). Latency-associated peptide also forms a disulfi de linkage with proteins of the latent TGF-β binding protein (LTBP) family. Latent TGF-β binding proteins, in turn, are covalently attached to extracellular matrix proteins. 32 Latent TGF-β must be released from LAP before it can bind to its receptors. This process, called latent TGFb activation, is highly regulated and can be accomplished in several ways. 32 Proteases (plasmin and several matrix metalloproteinases) can degrade LAP and release TCFβ-1. Reactive oxygen species activate latent TGF-β1 by denaturing LAP. Thrombospondin-1 binds to LAP, triggering a conformational change that releases active TGFβ. Finally, the integrins αvβ6 and αvβ8 activate TGF-β1 by binding to an integrin binding motif (arginine-glycineaspartic acid) near the C terminus of LAP.

Sime et al. demonstrated the critical importance TGFβ activation in lung fi brosis. 28 Using an adenoviral system, they expressed either wild-type TGF-β1 or a mutated form bearing mutations in the LAP domain that eliminate the inhibitory function of LAP. Only the constitutively active form of TGF-β1 produced fi brosis, despite the presence of high lung levels of total TGF-β1 protein in both cases. This result indicates that TGF-β activating capacity, rather than the amount of substrate (latent TGF-β), can be the limiting factor in TGF-β-mediated fi brotic lung reactions.

αvβ6-mediated TGF-β activation appears to be a particularly important activation mechanism in the lung. Integrins are heterodimeric cell surface receptors, each composed of an αand a β-subunit. αvβ6 is one of 24 mammalian integrins, 8 of which bind arginine-glycineaspartic acid sequences. αvβ6 is mainly expressed in epithelial cells. Activation of TGF-β1 by αvβ6 requires an intact actin cytoskeleton and tethering of latent TGF-β1 to the extracellular matrix by LTBP1. 33 Proteaseactivated receptor-1 signaling enhances actin contractility and αvβ6-mediated TGF-β1 activation. 34 In the lung, αvβ6 normally is expressed at a low level but is sharply upregulated by infl ammatory stimuli. β6-integrin knockout mice develop lung infl ammation and ultimately emphysema, are protected from acute lung injury, and are resistant to fi brosis. 35, 36 All these effects are due to, or at least consistent with, reduced TGF-β signaling. Bleomycin-treated β6 knockout mice have more lung infl ammation than wild-type controls, indicating that infl ammation and fi brosis can be dissociated. Other mechanisms of TGF-β activation in the lung may also come into play; for example, IL-13-dependent lung fi brosis is dependent on TGF-β signaling, and proteases (plasmin and matrix metalloproteinases) appear to be the activators. 29, 30 Also, bleomycin-stimulated alveolar macrophages activate TGF-β using plasmin and thrombospondin-1. 37 Once activated, TGF-β sets in motion a wide range of profi brotic processes (Figure 46.3) . In addition to its direct effects, TGF-β upregulates other profi brotic molecules such as platelet-derived growth factor, ROS, and connective tissue growth factor. Connective tissue growth factor, a member of the CCN family of matricellular proteins, is a downstream mediator of TGF-β effects. Its signaling function is not well understood but may derive in part from its ability to enhance binding of TGF-β to TGF-β receptors. 38 Transforming growth factor-β signal-ing causes autoinduction of the TGFb-1 gene and upregulation of TGF-β activators (αvβ6 and ROS), suggesting the possibility of a positive feedback loop in TGF-β signaling. Endogenous negative regulators of TGF-β signaling include an inhibitory Smad (Smad7), which is induced by TGF-β, and extracellular molecules such as decorin and α 2 -macroglobulin. Impaired Smad7 expression may contribute to scarring in scleroderma. 39 

Accumulating evidence supports the intriguing hypothesis that chronic viral infection of alveolar epithelial cells triggers fi brosis in susceptible hosts. 40 Tang et al. 41 found that 97% of IPF biopsy specimens were positive for one or more of four herpesviruses tested compared with only 36% of controls, and others have reported the presence of actively replicating Epstein-Barr virus (EBV) in IPF lung. 42 Although EBV DNA can be detected in the blood of most people, it is less commonly detected in the lung; EBV can be detected in lungs of IPF patients about four times more frequently than in controls. Furthermore, a specifi c form of EBV (the Wzhet rearrangement) that favors active replication was found to occur much more frequently in IPF patients (59%) than in controls (2%). 42 Causality cannot be proved in such studies but can be assessed in animal models. The murine γ-herpesvirus 68 (MHV68), analogous to EBV, has been used in several studies. 40 BALB/c mice, normally fi brosis resistant, develop fi brosis if infected with MHV68 prior to bleomycin injury. Also, MHV68 infection of interferon receptor knockout mice results in lung fi brosis with many of the pathologic features of human UIP/IPF.

Idiopathic pulmonary fi brosis lungs have abnormal anastomoses between the systemic and pulmonary circulations, and neovascularization also occurs in animal models. In addition, extracts of fi brotic lungs have angiogenic activity when tested in the corneal pocket assay. Strieter and colleagues showed that the abnormal angiogenic activity of fi brotic lung is due to an imbalance between angiogenic CXC chemokines (e.g., CXCL5 and CXCL8, which signal through the receptor CXCR2) and interferon-inducible angiostatic CXC chemokines (CXCL9, CXCL10, and CXCL11, which signal through CXCR3). 43, 44 Increasing angiostatic activity (e.g., by administration of recombinant CXCL10 or CXCL11) or reducing angiogenic activity (e.g., in CXCR2 knockout mice) reduces fi brosis in the bleomycin model, supporting the concept that neovascularization may be causally connected to the fi brotic process. The central role of transforming growth factor-β (TGF-β) in lung fi brosis. Latent TGF-β is converted to active TGF-β by thrombospondin-1 (TSP-1), αvβ6 integrin, proteases, or reactive oxygen species (ROS). Transforming growth factor-β may positively regulate its own signaling by upregulating two activation mechanisms (ROS and αvβ6 expression) and autoinducing transcription of the TGF-β1 gene. Transforming growth factor-β signaling also positively regulates multiple fi brogenic factors and processes. CTGF, connective tissue growth factor; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; MMPs, matrix metalloproteinases; PDGF, plateletderived growth factor; SP, surfactant protein.

Surfactant protein C (SP-C) mutations are the bestcharacterized genetic cause of IPF-like lung disease. Surfactant protein C is produced by AT2 cells and contributes to the surface tension-reducing properties of surfactant and to innate immune defense. Because of its hydrophobicity and tendency to form insoluble aggregates, including amyloid fi brils in aqueous solution, SP-C poses a processing challenge to the AT2 cell. The 3.7-kDa mature protein is generated from a 21-kDa precursor ( Figure  46.4) . Surfactant protein C processing involves translocation of the proprotein to the endoplasmic reticulum, folding, and addition of two palmitic acid residues, a total of four proteolytic cleavages of the N-and C-terminal propeptide domains to generate mature SP-C, release of SP-C into the lumen of the lamellar body where it associates with surfactant phospholipids and proteins, and secretion into the alveolar space. 45 Surfactant protein C mutations in patients with interstitial lung disease occur in several locations and act in an autosomal dominant fashion. Almost all mutations occur in the luminal part of the proprotein, and most are within the ≈100 amino acid C-terminal region (Phe94-Ile197) that forms a so-called BRICHOS domain. The BRICHOS domain affects targeting, processing, and folding of proteins that contain them.

The clinical manifestations of these mutations are varied. Some patients present within weeks of birth, whereas others manifest disease as adults. Pathologic fi ndings range from UIP and nonspecifi c interstitial pneumonia to pulmonary alveolar proteinosis.

The molecular basis of the lung disease appears to be loss of normal SP-C levels in surfactant and/or toxic effects of misfolded mutant SP-C within the AT2 cell. The toxic "gain-of-function" effects of mutant proteins have been studied by expressing mutant SP-C in epithelial cells. Depending on the mutation and level of expression, mutant protein accumulates in the endoplasmic reticulum, in perinuclear collections termed aggresomes or in endosomal vesicles. Misfolded protein can induce the endoplasmic reticulum stress response, leading to apoptosis or increased expression of infl ammatory mediators. 46 Also, accumulations of mutant protein may be directly toxic to the cell, as postulated for other proteins that form amyloid.

Mutant SP-C acts in a dominant-negative fashion to block release of wild-type, mature SP-C. This effect appears to be restricted to SP-C mutations within the BRICHOS domain; patients with these mutations fail to secrete mature SP-C. Amin and colleagues described a patient with interstitial lung disease who had no detectable mature SP-C within the lung despite the absence of mutations within the SP-C gene coding regions, suggesting that absence of SP-C may cause lung disease. 47 However, patients with SP-C mutations outside the BRICHOS domain produce mature SP-C, suggesting that toxic gain-of-function effects may be the dominant mechanism leading to lung disease.

Mice lacking SP-C or overexpressing mutant SP-C have lung abnormalities but do not recapitulate the fi ndings found in humans. Surfactant protein C knockout mice are viable and develop lung infl ammation and emphysema; when exposed to bleomycin they have an exag gerated fi brotic response. 48 Mice overexpressing a mutant SFTPC transgene lacking much of the BRICHOS domain have a lethal disruption of branching morphogenesis. 49 Figure 46 .4. Schematic diagram of prosurfactant protein C and mutations that cause interstitial lung disease. Mature surfactant protein C (SP-C) is shown in blue. Pro-SP-C associates with the cell membrane via a transmembrane domain and two palmitic acid residues before it is translocated into the lumen of the lamellar body. After removal of the N-and C-terminal prodomains, mature SP-C is translocated to the lumen of the lamellar body where it associates with the other constituents of surfactant. Lamellar bodies are lysosome-related organelles unique to AT2 cells. Amino acid substitutions causing interstitial lung disease are shown in green. Two deletions causing interstitial lung disease are shown in red. The mutations interfere with normal processing, causing protein aggregation and in some cases impaired secretion of mature SP-C.

Hermansky-Pudlak syndrome (HPS) is another inherited disorder leading to interstitial lung disease, and, interestingly, the defect also targets AT2 cells. Hermansky-Pudlak syndrome is due to mutations in one of eight genes in humans (HPS1-8) [50] [51] [52] ; corresponding mutations occur in mice (Table 46. 3). Patients manifest reduced skin and eye pigmentation, a bleeding diathesis due to platelet dysfunction, and, in some cases, progressive lung fi brosis in middle age. The defect underlying these abnormalities is impaired genesis or function of lysosome-related organelles. 51 These organelles are variants of lysosomes that perform specialized functions. The affected organelles are melanosomes in melanocytes, cytotoxic granules in lymphocytes, platelet dense granules, and lamellar bodies in AT2 cells. Biopsy specimens reveal proliferative, enlarged AT2 cells containing giant lamellar bodies packed with surfactant. The AT2 cells appear degenerative and often desquamated. There is infl ammation centered on respiratory bronchioles and fi brosis with honeycombing.

The disorder is autosomal recessive and involves two classes of genes. One group encodes proteins with known roles in protein traffi cking (e.g., adaptor protein-3). The second group encodes proteins that are subunits of protein complexes called BLOCs (biogenesis of lysosome-related organelles complex). The BLOCs are ubiquitously expressed, but the cellular localization and precise function of these multiprotein complexes have not been defi ned.

While the mouse strains with HPS mutations have pigmentation and platelet defects that mimic HPS, the lung pathology is quite different. 52 The HPS-like strains in general have reduced life spans and develop emphysema. Lyerla and colleagues generated a double homozygous mutant (HPS1 and HPS2 genes); the AT2 cells in these mice are enlarged and contain enlarged lamellar bodies engorged with surfactant, as well as signifi cant infl ammation, as seen in humans with HPS lung disease. 53 The mechanism connecting the genetic defects and lung fi brosis in humans is not known. Toxicity to AT2 cells and/or reductions in surfactant components may be involved. Toxicity to AT2 cells is readily apparent in biopsy tissues of patients. Alterations in surfactant secretion in patients have not been defi ned. In HPS1/HPS2 double mutant mice, total lung phospholipid, SP-B, and SP-C levels are increased (and SP-C is processed to the 3.7-kDa form), but alveolar levels of these components are reduced and isolated AT2 cells from these mice have reduced basal and stimulated phospholipid secretion. 52, 53 Genetic Studies of Sporadic and Familial Interstitial Lung Disease Case-control studies have been carried out to test the association of polymorphic variants of candidate genes with the risk for IPF. Positive results have been reported for genes encoding angiotensin-converting enzyme, complement receptor-1, IL-1 receptor antagonist, TNF-α, and SP-A and SP-B. 54 Interestingly, the SP-A1 variant (6A 4 ) encodes a protein with an altered amino acid (tryptophan rather than arginine) that appears to affect aggregation. 55 Sometimes interstitial lung disease cases cluster within families. Inheritance is autosomal dominant with reduced penetrance. In about half the families the disease is uniformly UIP/IPF, and in the others there are various presentations (as occurs in families with SP-C mutations). 

Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fi brosis

Idiopathic pulmonary fi brosis: an epithelial/fi broblastic cross-talk disorder

Lung infection with gamma-herpesvirus induces progressive pulmonary fi brosis in Th2-biased mice

An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fi brosis

Alveolar epithelial cell death adjacent to underlying myofi broblasts in advanced fi brotic human lung

Discoidin domain receptor 1 contributes to the survival of lung fi broblast in idiopathic pulmonary fi brosis

Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fi brosis

Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fi brosis

Evidence that fi broblasts derive from epithelium during tissue fi brosis

Peripheral blood fi brocytes: differentiation pathway and migration to wound sites

Circulating fi brocytes defi ne a new leukocyte subpopulation that mediates tissue repair

Circulating fi brocytes traffi c to the lungs in response to CXCL12 and mediate fi brosis

The Role of CCL12 in the recruitment of fi brocytes and lung fi brosis

Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fi brosis

TGF-β1 induces alveolar epithelial to mesenchymal transition in vitro

Oxidative stress and regulation of glutathione in lung infl ammation

Glutathione deficiency in the epithelial lining fl uid of the lower respiratory tract in idiopathic pulmonary fi brosis

Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofi broblasts

Redox-mediated activation of latent transforming growth factor-β1

Nrf2 defends the lung from oxidative stress

High-dose acetylcysteine in idiopathic pulmonary fi brosis

Evolving concepts of apoptosis in idiopathic pulmonary fi brosis

Transgenic Modeling of Transforming Growth Factor-β1: Role of Apoptosis in Fibrosis and Alveolar Remodeling

Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fi brosis

Apoptosis in lung injury and remodeling

Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic infl ammatory lung disease

TGF-β and fi brosis

Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fi brosis in rat lung

Transient transgene expression of decorin in the lung reduces the fi brotic response to bleomycin

Interleukin-13 induces tissue fi brosis by selectively stimulating and activating transforming growth factor β

Mechanisms of TGF-β signaling from cell membrane to the nucleus

Making sense of latent TGFβ activation

Integrin αvβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1

Ligation of protease-activated receptor 1 enhances αvβ6 integrin-dependent TGF-β activation and promotes acute lung injury

The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary infl ammation and fi brosis

Loss of integrin αvβ6-mediated TGF-β activation causes MMP12-dependent emphysema

Activation of rat alveolar macrophage-derived latent transforming growth factor β1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36

Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β

Defi cient Smad7 expression: a putative molecular defect in scleroderma

Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fi brosis?

Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fi brosis

A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fi brosis

CXC chemokines in angiogenesis related to pulmonary fi brosis

CXCL11 attenuates bleomycin-induced pulmonary fi brosis via inhibition of vascular remodeling

Surfactant protein C biosynthesis and its emerging role in conformational lung disease

A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation

Surfactant protein defi ciency in familial interstitial lung disease

Increased and prolonged pulmonary fi brosis in surfactant protein C-defi cient mice following intratracheal bleomycin

Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice

A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8)

Insights into the biogenesis of lysosomerelated organelles from the study of the Hermansky-Pudlak syndrome

Murine Hermansky-Pudlak syndrome genes: regulators of lysosome-related organelles

Aberrant lung structure, composition, and function in a murine model of Hermansky-Pudlak syndrome

Genetics of fi brosing lung diseases

Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fi brosis